

# Radiopharmaceuticals (Nuclear Medicine) Market, 2012 to 2023

<https://marketpublishers.com/r/RE3F90C6B6CEN.html>

Date: January 2018

Pages: 206

Price: US\$ 4,400.00 (Single User License)

ID: RE3F90C6B6CEN

## Abstracts

Global Radiopharmaceuticals (Nuclear Medicine) Market: By Product Type (Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)), By Application (Oncology, Neurological disorders, Cardiovascular diseases, Thyroid, and Others), By Route of Administration (Oral, Inhalation, and Parenteral) By End User (Hospitals, Clinics, Diagnostic Centers, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Global Radiopharmaceuticals (Nuclear Medicine) Market Outline:

Global radiopharmaceuticals (nuclear medicine) market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US\$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies Global radiopharmaceuticals (nuclear medicine) market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key

stakeholders of the Global radiopharmaceuticals (nuclear medicine) market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.

#### Radiopharmaceuticals (Nuclear Medicine) Market:

Global radiopharmaceuticals (nuclear medicine) market estimated to be valued US\$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US\$ 8,564 Mn by 2023 owing to increasing adoption of radiotherapeutic and diagnostic procedures across the globe.

Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe

The global radiopharmaceuticals (nuclear medicine) market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period

Emergence of radiopharmaceuticals (nuclear medicine) as safer alternative to the conventional diagnosis

The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.

North America accounts for larger revenue share in global radiopharmaceuticals

(nuclear medicine) market

North America market holds the higher revenue share in global radiopharmaceuticals (nuclear medicine) market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia Pacific radiopharmaceuticals (nuclear medicine) market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region

### Competition Assessment

Key players profiled in the global radiopharmaceuticals (nuclear medicine) market include:

Advanced Accelerator Applications S.A. (France)

Bayer AG (Germany)

Bracco Imaging S.p.A (Italy)

Cardinal Health, Inc. (U.S.)

Eli Lilly and Co. (U.S.)

GE Healthcare (U.S.)

IBA Molecular Imaging (Belgium)

Jubilant Life Sciences Ltd (India)

Lantheus Medical Imaging, Inc. (U.S.)

Mallinckrodt plc (Ireland)

Navidea Biopharmaceutical (U.S.)

Nordion, Inc. (Canada)

Siemens Healthineers (Germany)

Players in the radiopharmaceuticals (nuclear medicine) market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals (nuclear medicine) market

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET INTRODUCTION**

2.1. Global Radiopharmaceuticals (Nuclear Medicine) Market – Taxonomy

2.2. Global Radiopharmaceuticals (Nuclear Medicine) Market –Definitions

2.2.1. Product Type

2.2.2. Application

2.2.3. Route of Administration

2.2.4. End-User

### **3. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET DYNAMICS**

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Factors Impact Analysis

3.6. Global Radiopharmaceuticals (Nuclear Medicine) Market – Regulations

3.6.1. U.S.

3.6.2. Europe

### **4. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023**

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

### **5. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023**

5.1. Diagnostic Radiopharmaceuticals

5.1.1. SPECT Radiopharmaceuticals

5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.1.3. Market Opportunity Analysis

5.1.2. PET Radiopharmaceuticals

5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.2.3. Market Opportunity Analysis

5.2. Therapeutic Radiopharmaceuticals

5.2.1. Beta Emitters

5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.1.3. Market Opportunity Analysis

5.2.2. Alpha emitters

5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.2.3. Market Opportunity Analysis

5.2.3. Brachytherapy

5.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3.3. Market Opportunity Analysis

5.2.4. Others

5.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.4.3. Market Opportunity Analysis

## **6. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023**

6.1. Oncology

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Neurological disorders

- 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.2.3. Market Opportunity Analysis
- 6.3. Cardiovascular diseases
  - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.3.3. Market Opportunity Analysis
- 6.4. Thyroid
  - 6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.4.3. Market Opportunity Analysis
- 6.5. Others
  - 6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.5.3. Market Opportunity Analysis

## **7. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 7.1. Oral
  - 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 7.1.3. Market Opportunity Analysis
- 7.2. Inhalation
  - 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 7.2.3. Market Opportunity Analysis
- 7.3. Parenteral
  - 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 7.3.3. Market Opportunity Analysis

## **8. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 8.1. Hospitals
  - 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

- 8.1.3. Market Opportunity Analysis
- 8.2. Clinics
  - 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 8.2.3. Market Opportunity Analysis
- 8.3. Diagnostic Centers
  - 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 8.3.3. Market Opportunity Analysis
- 8.4. Research Institutes
  - 8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 8.4.3. Market Opportunity Analysis

## **9. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 9.1. North America
  - 9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 9.1.3. Market Opportunity Analysis
- 9.2. Europe
  - 9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 9.2.3. Market Opportunity Analysis
- 9.3. Asia-Pacific
  - 9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 9.3.3. Market Opportunity Analysis
- 9.4. Latin America
  - 9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 9.4.3. Market Opportunity Analysis
- 9.5. Middle East and Africa
  - 9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 9.5.3. Market Opportunity Analysis
- 9.6. Global Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and

Region, 2017 – 2023

## **10. NORTH AMERICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

10.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Diagnostic Radiopharmaceuticals

10.1.1.1. SPECT Radiopharmaceuticals

10.1.1.2. PET Radiopharmaceuticals

10.1.2. Therapeutic Radiopharmaceuticals

10.1.2.1. Beta Emitters

10.1.2.2. Alpha emitters

10.1.2.3. Brachytherapy

10.1.2.4. Others

10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Oncology

10.2.2. Neurological disorders

10.2.3. Cardiovascular diseases

10.2.4. Thyroid

10.2.5. Others

10.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Oral

10.3.2. Inhalation

10.3.3. Parenteral

10.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.4.1. Hospitals

10.4.2. Clinics

10.4.3. Diagnostic Centers

10.4.4. Research Institutes

10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.5.1. U.S.

10.5.2. Canada

10.6. North America Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-



User, and Country, 2017 – 2023

10.7. North America Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

## **11. EUROPE RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

11.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Diagnostic Radiopharmaceuticals

11.1.1.1. SPECT Radiopharmaceuticals

11.1.1.2. PET Radiopharmaceuticals

11.1.2. Therapeutic Radiopharmaceuticals

11.1.2.1. Beta Emitters

11.1.2.2. Alpha emitters

11.1.2.3. Brachytherapy

11.1.2.4. Others

11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Oncology

11.2.2. Neurological disorders

11.2.3. Cardiovascular diseases

11.2.4. Thyroid

11.2.5. Others

11.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Oral

11.3.2. Inhalation

11.3.3. Parenteral

11.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.4.1. Hospitals

11.4.2. Clinics

11.4.3. Diagnostic Centers

11.4.4. Research Institutes

11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.5.1. Germany

11.5.2. UK

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Russia

11.5.7. Poland

11.5.8. Rest of Europe

11.6. Europe Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023

11.7. Europe Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

## **12. ASIA-PACIFIC RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

12.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Diagnostic Radiopharmaceuticals

12.1.1.1. SPECT Radiopharmaceuticals

12.1.1.2. PET Radiopharmaceuticals

12.1.2. Therapeutic Radiopharmaceuticals

12.1.2.1. Beta Emitters

12.1.2.2. Alpha emitters

12.1.2.3. Brachytherapy

12.1.2.4. Others

12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Oncology

12.2.2. Neurological disorders

12.2.3. Cardiovascular diseases

12.2.4. Thyroid

12.2.5. Others

12.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Oral

12.3.2. Inhalation

12.3.3. Parenteral

12.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.4.1. Hospitals

12.4.2. Clinics

12.4.3. Diagnostic Centers

12.4.4. Research Institutes

12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

12.5.1. Japan

12.5.2. China

12.5.3. India

12.5.4. ASEAN

12.5.5. Australia & New Zealand

12.5.6. Rest of Asia-Pacific

12.6. Asia-Pacific Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023

12.7. Europe Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

### **13. LATIN AMERICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

13.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Diagnostic Radiopharmaceuticals

13.1.1.1. SPECT Radiopharmaceuticals

13.1.1.2. PET Radiopharmaceuticals

13.1.2. Therapeutic Radiopharmaceuticals

13.1.2.1. Beta Emitters

13.1.2.2. Alpha emitters

13.1.2.3. Brachytherapy

13.1.2.4. Others

13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Oncology

13.2.2. Neurological disorders

13.2.3. Cardiovascular diseases

13.2.4. Thyroid

13.2.5. Others

13.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Oral

13.3.2. Inhalation

13.3.3. Parenteral

13.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.4.1. Hospitals

13.4.2. Clinics

13.4.3. Diagnostic Centers

13.4.4. Research Institutes

13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Argentina

13.5.4. Venezuela

13.5.5. Rest of Latin America

13.6. Latin America Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023

13.7. Latin America Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

## **14. MIDDLE EAST AND AFRICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

14.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.1. Diagnostic Radiopharmaceuticals

14.1.1.1. SPECT Radiopharmaceuticals

14.1.1.2. PET Radiopharmaceuticals

14.1.2. Therapeutic Radiopharmaceuticals

14.1.2.1. Beta Emitters

14.1.2.2. Alpha emitters

14.1.2.3. Brachytherapy

14.1.2.4. Others

14.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.2.1. Oncology

14.2.2. Neurological disorders

- 14.2.3. Cardiovascular diseases
- 14.2.4. Thyroid
- 14.2.5. Others
- 14.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 14.3.1. Oral
  - 14.3.2. Inhalation
  - 14.3.3. Parenteral
- 14.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 14.4.1. Hospitals
  - 14.4.2. Clinics
  - 14.4.3. Diagnostic Centers
  - 14.4.4. Research Institutes
- 14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 14.5.1. Gulf Cooperation Council (GCC) Countries
  - 14.5.2. Israel
  - 14.5.3. South Africa
  - 14.5.4. Rest of MEA
- 14.6. MEA Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
- 14.7. MEA Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

## **15. COMPETITION LANDSCAPE**

- 15.1. Strategic Dashboard of Top Market Players
- 15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  - 15.2.1. Advanced Accelerator Applications S.A. (France)
  - 15.2.2. Bayer AG (Germany)
  - 15.2.3. Bracco Imaging S.p.A (Italy)
  - 15.2.4. Cardinal Health, Inc. (U.S.)
  - 15.2.5. Eli Lilly and Co. (U.S.)
  - 15.2.6. GE Healthcare (U.S.)
  - 15.2.7. IBA Molecular Imaging (Belgium)
  - 15.2.8. Jubilant Life Sciences Ltd (India)
  - 15.2.9. Lantheus Medical Imaging, Inc. (U.S.)

- 15.2.10. Mallinckrodt plc (Ireland)
- 15.2.11. Navidea Biopharmaceutical (U.S.)
- 15.2.12. Nordion, Inc. (Canada)
- 15.2.13. Siemens Healthineers (Germany)

## **16. RESEARCH METHODOLOGY**

## **17. KEY ASSUMPTIONS AND ACRONYMS**

## I would like to order

Product name: Radiopharmaceuticals (Nuclear Medicine) Market, 2012 to 2023

Product link: <https://marketpublishers.com/r/RE3F90C6B6CEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RE3F90C6B6CEN.html>